NCT04971226 2026-04-06A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNovartisPhase 3 Active not recruiting405 enrolled 18 charts 3 FDA
NCT03106779 2025-04-08Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsNovartisPhase 3 Completed233 enrolled 10 charts 2 FDA
NCT02081378 2024-03-18A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLNovartisPhase 1 Completed326 enrolled 2 FDA